MA27998A1 - Nouvelle formulation - Google Patents

Nouvelle formulation

Info

Publication number
MA27998A1
MA27998A1 MA28819A MA28819A MA27998A1 MA 27998 A1 MA27998 A1 MA 27998A1 MA 28819 A MA28819 A MA 28819A MA 28819 A MA28819 A MA 28819A MA 27998 A1 MA27998 A1 MA 27998A1
Authority
MA
Morocco
Prior art keywords
new formulation
ropinirole
rls
diseases
treatment
Prior art date
Application number
MA28819A
Other languages
English (en)
Inventor
Peta Elizabeth Pollock
Julian Westrup
David Jonathan Yates
Original Assignee
Smithkline Beecham Cork Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Cork Ltd filed Critical Smithkline Beecham Cork Ltd
Publication of MA27998A1 publication Critical patent/MA27998A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Formulation nouvelle de ropinirole La présente invention concerne des formulations nouvelles de ropinirole pour administration orale, et leur utilisation dans le traitement de maladies qui peuvent empêcher ou perturber le sommeil, en particulier du syndrome des jambes sans repos (RLS).
MA28819A 2003-08-22 2006-02-17 Nouvelle formulation MA27998A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0319874.4A GB0319874D0 (en) 2003-08-22 2003-08-22 Novel formulation

Publications (1)

Publication Number Publication Date
MA27998A1 true MA27998A1 (fr) 2006-07-03

Family

ID=28460214

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28819A MA27998A1 (fr) 2003-08-22 2006-02-17 Nouvelle formulation

Country Status (19)

Country Link
US (1) US20070059365A1 (fr)
EP (1) EP1656118A2 (fr)
JP (1) JP2007503414A (fr)
KR (1) KR20060120596A (fr)
CN (1) CN1838945A (fr)
AR (1) AR045289A1 (fr)
AU (1) AU2004266072A1 (fr)
BR (1) BRPI0413632A (fr)
CA (1) CA2536414A1 (fr)
GB (1) GB0319874D0 (fr)
IL (1) IL173440A0 (fr)
IS (1) IS8352A (fr)
MA (1) MA27998A1 (fr)
MX (1) MXPA06002023A (fr)
NO (1) NO20061291L (fr)
RU (1) RU2006109010A (fr)
TW (1) TW200517107A (fr)
WO (1) WO2005018605A2 (fr)
ZA (1) ZA200600719B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080078075A (ko) 2005-12-20 2008-08-26 세레우사이언스 아베 하지 불안 증후군의 치료 및 진단을 위한 방법 및 조성물
US20100136125A1 (en) * 2006-12-28 2010-06-03 Jacobus Pharmaceutical Company, Inc. Method of treating inflammatory bowel disease
EP2022496A1 (fr) * 2007-07-16 2009-02-11 Ranbaxy Laboratories Limited Compositions stables de ropinirole
WO2009023761A2 (fr) * 2007-08-14 2009-02-19 Dr. Reddy's Laboratories Ltd. Compositions pharmaceutiques comprenant du ropinirole
US20090076124A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched ropinirole
WO2009078034A2 (fr) * 2007-11-26 2009-06-25 Rubicon Research Private Limited Comprimés de chlorhydrate de ropinirole se désintégrant par voie orale
CN101574341B (zh) * 2008-05-05 2012-12-19 北京德众万全医药科技有限公司 一种罗匹尼罗的口服固体药物组合物
SI22849A (sl) * 2008-08-01 2010-02-26 Krka, Tovarna Zdravil, D.D., Novo Mesto Ropinirolni pripravek
WO2010015911A1 (fr) * 2008-08-06 2010-02-11 Torrent Pharmaceuticals Limited Compositions pharmaceutiques à libération prolongée de ropinirole et leur procédé de préparation
WO2010023693A2 (fr) * 2008-09-01 2010-03-04 Lupin Limited Nouvelles compositions de ropinirole à libération contrôlée
CA2738414C (fr) 2008-09-29 2014-05-27 Wockhardt Research Centre Forme posologique a liberation prolongee de ropinirole
WO2010044108A2 (fr) 2008-10-17 2010-04-22 Rubicon Research Private Limited Formulations à libération contrôlée de ropinirole
MX381895B (es) * 2009-02-13 2025-03-13 Romark Laboratories Lc Formulaciones farmaceuticas de liberacion controlada de nitazoxanida.
WO2011032416A1 (fr) * 2009-09-19 2011-03-24 浙江华海药业股份有限公司 Composition pharmaceutique contenant un agoniste des récepteurs de la dopamine
KR101068476B1 (ko) * 2009-12-29 2011-09-28 환인제약 주식회사 로피니롤 경구 투여용 서방성 제제
GR1007629B (el) * 2011-07-13 2012-06-29 Φαρματεν Αβεε, Φαρμακευτικο σκευασμα ελεγχομενης αποδεσμευσης ενος μη εργολινικου αγωνιστη της ντοπαμινης
EP2806861A1 (fr) * 2012-01-23 2014-12-03 Ranbaxy Laboratories Limited Technologie de comprimé multicouche in situ
ITFI20130189A1 (it) * 2013-08-05 2015-02-06 Valpharma Internat S P A Una composizione farmaceutica contenente ropinirolo hcl somministrabile per via orale e metodo di produzione.
US9463889B2 (en) * 2013-10-25 2016-10-11 Medtronic, Inc. Prefilled reservoir apparatus for ambulatory infusion device
CN104188931B (zh) * 2014-08-25 2017-06-16 泰州越洋医药开发有限公司 一种盐酸罗匹尼罗固体口服控释片剂及其制备方法
CN104473893A (zh) * 2014-11-21 2015-04-01 哈尔滨圣吉药业股份有限公司 一种盐酸罗匹尼罗缓释片及其制备方法
US10653699B2 (en) 2015-06-19 2020-05-19 Biotie Therapies, Inc. Controlled-release tozadenant formulations
EP4066829A4 (fr) * 2019-11-26 2023-12-27 Hisamitsu Pharmaceutical Co., Inc. Procédé améliorant la résistance de collage de couche d'adhésif pour timbre transdermique comprenant un ropinirole, et timbre transdermique de meilleure résistance de collage comprenant un ropinirole
CN114727965B (zh) * 2019-12-23 2023-12-12 江苏恒瑞医药股份有限公司 一种jak激酶抑制剂药物组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1188212B (it) * 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
IT1237904B (it) * 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
IT1265240B1 (it) * 1993-11-30 1996-10-31 Ekita Investments Nv Compressa farmaceutica a rilascio controllato, di forma lenticolare
US20010029262A1 (en) * 1998-06-29 2001-10-11 Sethi Kapil Dev Method of treatment or prophylaxis
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
GB0125088D0 (en) * 2001-10-18 2001-12-12 Smithkline Beecham Cork Ltd New use
WO2004000263A1 (fr) * 2002-06-25 2003-12-31 Acrux Dds Pty Ltd Commande de debit d'apport transdermique utilisant des compositions pharmaceutiques amorphes

Also Published As

Publication number Publication date
ZA200600719B (en) 2007-03-28
TW200517107A (en) 2005-06-01
EP1656118A2 (fr) 2006-05-17
WO2005018605A3 (fr) 2005-11-03
CN1838945A (zh) 2006-09-27
BRPI0413632A (pt) 2006-10-17
KR20060120596A (ko) 2006-11-27
GB0319874D0 (en) 2003-09-24
JP2007503414A (ja) 2007-02-22
IS8352A (is) 2006-03-14
MXPA06002023A (es) 2006-05-17
US20070059365A1 (en) 2007-03-15
CA2536414A1 (fr) 2005-03-03
WO2005018605A2 (fr) 2005-03-03
RU2006109010A (ru) 2006-08-10
NO20061291L (no) 2006-05-16
IL173440A0 (en) 2006-06-11
AR045289A1 (es) 2005-10-19
AU2004266072A1 (en) 2005-03-03

Similar Documents

Publication Publication Date Title
TW200517107A (en) Novel formulation
ATE491436T1 (de) Zusammensetzungen gegen infektionen zur behandlung erkrankten gewebes wie z.b. fieberbläschen
BRPI0407583A (pt) solução oftálmica lìmpida e estável
PT1347971E (pt) Inibidores tiazolilicos de tirosina-cinases da familia tec
DE60019473D1 (de) (S,S)-Reboxetin zur Behandlung von peripheren Neuropathien
EA200100872A1 (ru) Композиция валдекоксиба
PL352318A1 (en) Fish serine proteinases, and pharmaceutical and cosmetic use of same
TR200200065T2 (tr) Dış salgılama bozukluklarının tedavisi için terkip
YU49202A (sh) Benzazolski derivati i njihova upotreba kao modulatora jnk
PL375621A1 (pl) Kompozycje farmaceutyczne zawierające flawonoidy i mentol
TNSN00010A1 (fr) DIPHENYLUREE A SUBSTITUTION ω CARBOXYARYLE SERVANT D'INHIBUTEURS DE RAF KINASE.
JO2356B1 (en) N-by-phenyl derivatives (methyl substituted) amino cycloalkan carboxamide
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
MA27929A1 (fr) Utilisation de calcitonine pour le traitement de l'osteoarthrite
EE200400005A (et) Tablett, mis sisaldab vähemalt kahte eristatavat segmenti ning selle kasutamine
DE60229417D1 (de) Setzungen auf basis von pyrogenisch hergestelltem siliziumdioxid
EP1476419A4 (fr) Derives de n-biphenylmethyl aminocycloalcanecarboxamide
DK1228097T3 (da) Antimikrobiel aktivitet af den förste kationiske humane lactoferrin-klynge
EP1578373A4 (fr) Nouvelles compositions et methodes pour le traitement de maladies associees au systeme immunitaire
EP1581243A4 (fr) Lactoferrine orale pour le traitement des sepsies
DE60202590D1 (de) 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
SE0001916D0 (sv) Novel formulation
EA200500031A1 (ru) Быстрораспадающаяся таблетка
DE60208701D1 (de) Verwendung von cetrorelix zur behandlung vom jakob-creutzfeldt-syndrom
DK1273301T3 (da) Farmaceutiske præparater baseret på aktive bestanddele der kan anvendes til ulovlig administration